Ahmad Ghorab

Assistant Professor

Baylor College of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Ahmad Ghorab is an Assistant Professor at Baylor College of Medicine in the United States. His research areas include hematology, specifically focusing on myelodysplastic syndromes and acute myeloid leukemia, as well as gastrointestinal cancers and lymphomas. Recent publications highlight his contributions to understanding patient outcomes in relation to various treatment strategies in these fields.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (1)

Hemant Murthy

assistant professor of medicine

Mayo Clinic Research Florida

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ahmad Ghorab

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Younger haplo-donors improve older patient survival outcomes

Real-World Epidemiological Analysis of Gastrointestinal Neuroendocrine Carcinomas: A TriNetX-Based Study

Heyde’s syndrome: a challenging case of severe aortic stenosis and gastrointestinal bleeding

Clinicopathologic Features and Survival Outcomes of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) of the Urothelial Organs (Urologic MALT Lymphoma): The Mayo Clinic Experience (2013-2022)

Experience with Gray Zone Lymphoma (GZL) at Mayo Clinic: A Review of Clinical Characteristics and Treatment Outcomes

AML-497 Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs

Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)

MDS-353 Clinical Outcome of Myelodysplastic Syndrome Progressing on Hypomethylating Agents With Evolving Frontline Therapies: Continued Challenges and Unmet Needs

Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies

Collaborators (1)

Hemant Murthy

Make your next move.